EN DE
Watch Beta Bionics, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beta Bionics, Inc. (BBNX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Beta Bionics, Inc. stock $4.17, price $15.70, that is 73.4% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BB Beta Bionics, Inc. logo Thin data Nov 6, 2026

Beta Bionics, Inc.

BBNX · US
Very expensive, weak quality

Our calculation puts a fair price 73% below what the stock costs today.

Revenue last quarter +30% vs. a year ago.
Expensive Growth (revenue 3y +724.3 %/yr in USD)
Neutral coverage
Insiders sold $3.2M (6M)
Fair value $4.17 · Strongly overvalued (−73.4%)
Quality 32/100
Loss-making · -65.3% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 10/100 · thin data
Thin data
Watch Beta Bionics, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$31.99 $8.86 Fair Value $4.17 Jan 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

21‑month range $8.86 – $31.99 · fair‑value band $2.75 – $5.21 · the $15.70 price screens above the $4.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Beta Bionics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Beta Bionics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Show moreShow less

It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.

The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.

It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.

The company was incorporated in 2015 and is headquartered in Irvine, California.

Stock analysis

Beta Bionics, Inc. (BBNX) currently trades at $15.70, while our model-based Fair Value estimate is $4.17, 73% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: $2.75 (bear) to $5.21 (bull), the price of $15.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Beta Bionics, Inc. Common Stock reported revenue of $100M in FY2025 versus $179K in FY2022, a compound +724.3%/yr. Reported net income was −$73.2M in FY2025.

Key figures

Market cap $854M Small · P/S ratio 7.16 · EPS (TTM) $−1.83 · Net margin −65.3% · Return on equity −23.9% · Return on assets (EBIT) −67.5% (4-year average) · Operating margin −74.9% · Revenue (TTM) $127M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and 77% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −73%, BBNX screens richer than that median.

Fair Value models

Bear $2.75 Fair Value $4.17 Bull $5.21
Price $15.70 · Downside -73.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $2.75 $4.17 $5.21 52
All 1 models by family
Asset-Based
NCAV (Graham) $2.75 $4.17 $5.21 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 27
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 48
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors sold shares worth $3.2M and none bought.

  • SaleMark HopmanChief Commercial Officer14× since Dec 2, 2025: 86,177 shares, avg. $18.95$1.6MNov 2, 2026
  • SaleMike MensingerChief Product Officer8× since Dec 2, 2025: 26,180 shares, avg. $22.80$596,924Oct 27, 2026
  • SaleChristy JonesDirector4× since May 21, 2026: 12,645 shares, avg. $18.05$228,214Sep 22, 202610b5-1 plan
  • SaleSean SaintPresident & CEO, Director5× since Dec 2, 2025: 46,042 shares, avg. $17.08$786,358Sep 3, 2026
  • SaleStephen FeiderChief Financial Officer6× since Dec 2, 2025: 46,206 shares, avg. $22.34$1.0MSep 2, 2026
  • SaleSteven Jon RussellChief Medical Officer4× since Dec 2, 2025: 10,494 shares, avg. $16.83$176,658Sep 2, 2026
  • SaleAdam LezackDirector2× since Dec 1, 2025: 3,404 shares, avg. $18.41$62,684May 22, 202610b5-1 plan
  • SaleMaria PalasisDirector1,406 shares at $29.55$41,553Dec 1, 202510b5-1 plan

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+53.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+724.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36,784.4% (2022) → −71.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BBNX screens overvalued: fair value 73% below the price. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (72 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Beta Bionics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −73.4% · Bottom 25%
Profitability
Return on assets −22.3% · Bottom 25%
Net margin (12 months) −65.3% · Bottom 25%
Operating margin (12 months) −74.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 30.3% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.97× · Pricier than median
P/S (12 months) 6.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)100 · sector 35
PAST (return on equity)0 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs BBNX
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs BBNX
DexCom, Inc DXCM $79.41 $87.35 +10% vs BBNX
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs BBNX
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs BBNX
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs BBNX
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs BBNX
Abbott Laboratories, ABT $109.93 $75.28 −32% vs BBNX
Medtronic plc MDT $101.80 $65.61 −36% vs BBNX
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs BBNX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beta Bionics, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beta Bionics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/BBNX

Frequently asked questions

Is Beta Bionics, Inc. (BBNX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $4.17 versus a price of $15.70, about 73% lower (overvalued).
What is the fair value of BBNX?
Our model-based fair value for Beta Bionics, Inc. is $4.17 (as of Nov 6, 2026), built from audited fundamentals. The current price: $15.70.
What is the quality score of BBNX?
Beta Bionics, Inc. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beta Bionics, Inc. (BBNX)?
Our model-based price target is the fair value of $4.17 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $2.75, optimistic scenario $5.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Beta Bionics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $4.17, about 73% lower versus a price of $15.70 (overvalued). Cautious scenario $2.75, optimistic scenario $5.21. The calculation is refreshed regularly with new filings.
What is the revenue of Beta Bionics, Inc. (BBNX)?
Beta Bionics, Inc. reported trailing-twelve-month revenue of about $127M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Beta Bionics, Inc. (BBNX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beta Bionics, Inc. it is $4.17 per share (as of Nov 6, 2026), against a price of $15.70. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Beta Bionics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BBNX trades above its calculated fair value: price $15.70, fair value $4.17, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BBNX?
No. The price is what the market pays today ($15.70); the fair value is what the company's own numbers justify ($4.17). For Beta Bionics, Inc. the two are $11.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beta Bionics, Inc. Common Stock worth?
The market values Beta Bionics, Inc. at about $854M (market capitalisation, as of Nov 6, 2026). Per share that is $15.70; our models calculate a fair value of $4.17 per share.
What do the bullish and bearish scenarios say about BBNX?
Our models span a range for Beta Bionics, Inc.: cautious scenario $2.75, base $4.17, optimistic $5.21 per share (as of Nov 6, 2026, price $15.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beta Bionics, Inc. (BBNX)?
Balance-sheet figures for Beta Bionics, Inc. (as of Nov 6, 2026): return on equity −23.9%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is BBNX from its 52-week high?
Beta Bionics, Inc. trades at $15.70, about 51% below its 52-week high of $31.99 and 77% above the low of $8.86 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $4.17 is for.
Which stocks are comparable to Beta Bionics, Inc. Common Stock?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beta Bionics, Inc. Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $15.70, calculated fair value $4.17 (−73%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BBNX calculated?
We run Beta Bionics, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $4.17 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beta Bionics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beta Bionics, Inc. (BBNX)?
The closing price on Nov 6, 2026 was $15.70. Our model-based fair value is $4.17, about 73% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beta Bionics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($5.21). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.75 to $5.21) leaves room in how you read the outcome.

Key figures of Beta Bionics, Inc.

How large is the market capitalisation of Beta Bionics, Inc. (BBNX)?
The market capitalisation of Beta Bionics, Inc. is $854M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beta Bionics, Inc. (BBNX)?
The price-to-sales ratio of Beta Bionics, Inc. is 7.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beta Bionics, Inc. (BBNX)?
Earnings per share at Beta Bionics, Inc. are $−1.83. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Beta Bionics, Inc. (BBNX)?
The net margin of Beta Bionics, Inc. is −65.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beta Bionics, Inc. (BBNX)?
The return on equity (ROE) of Beta Bionics, Inc. is −23.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beta Bionics, Inc. (BBNX)?
On an EBIT basis the return on assets of Beta Bionics, Inc. is −67.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beta Bionics, Inc. (BBNX)?
The operating margin of Beta Bionics, Inc. is −74.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beta Bionics, Inc. (BBNX)?
Revenue at Beta Bionics, Inc. is growing +30.3% versus a year earlier (3y avg +724%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beta Bionics, Inc. (BBNX) generate?
The free cash flow of Beta Bionics, Inc. is −$56.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beta Bionics, Inc. (BBNX) hold?
Beta Bionics, Inc. holds more cash than debt, $24.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beta Bionics, Inc. Common Stock in the live analysis

One click puts Beta Bionics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.